^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HRD + BRCA1 mutation

    i
    Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset, HRD, Homologous Recombination Deficiency
    Entrez ID:
    672
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (LUNG-MAP Sub-Study) (NCT03845296)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2019
    Primary completion :
    01/01/2022
    Completion :
    07/01/2024
    EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation
    |
    Rubraca (rucaparib)
    Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087)
    Phase 1/2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/02/2018
    Primary completion :
    03/31/2021
    Completion :
    08/09/2025
    BRCA1 • BRCA2 • HRD • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation
    |
    5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) (NCT04983745)
    Phase 2
    West Cancer Center
    Recruiting
    Last update posted :
    12/21/2023
    Initiation :
    11/29/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI
    |
    BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) (NCT04692740)
    Phase 2
    Michele Reni
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    12/18/2020
    Primary completion :
    01/04/2023
    Completion :
    12/01/2023
    BRCA1 • BRCA2 • HRD
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation
    |
    Leukeran (chlorambucil)
    A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) (NCT02952534)
    Phase 2
    zr Pharma & GmbH
    Completed
    Last update posted :
    06/09/2023
    Initiation :
    02/15/2017
    Primary completion :
    07/18/2021
    Completion :
    07/27/2021
    BRCA1 • BRCA2 • HRD
    |
    BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation
    |
    Rubraca (rucaparib)
    Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (NCT05597527)
    Phase 2
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    10/28/2022
    Initiation :
    11/01/2022
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation
    |
    AiTan (rivoceranib)
    Variance of HRD From Paired Ovarian Cancer (HOPEII) (NCT05069818)
    Phase N/A
    Xiaoxiang Chen
    Not yet recruiting
    Last update posted :
    10/06/2021
    Initiation :
    10/01/2021
    Primary completion :
    10/01/2022
    Completion :
    12/01/2022
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation
    Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors (POLA) (NCT02684318)
    Phase 1/2
    Poveda, Andrés, M.D.
    Unknown status
    Last update posted :
    06/22/2017
    Initiation :
    07/01/2015
    Primary completion :
    07/01/2019
    Completion :
    10/01/2019
    BRCA1 • PTEN • PARP1
    |
    BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation
    |
    Lynparza (olaparib) • Zepzelca (lurbinectedin)